Researchers evaluated a case study of a patient who was diagnosed with frontotemporal behavioral dementia whose autopsy showed coexistent TDP-43 type A and Alzheimer disease pathologies and cerebrovascular disease.
In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
A physically and mentally active lifestyle may protect against frontotemporal dementia even in people at established genetic risk.
There are currently no treatments available for frontotemporal dementia.
Investigators sought to identify genetic factors that may contribute to the risk for neurodegenerative diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.
The investigators hope that the findings from the study help raise awareness of frontotemporal dementia in geriatric patients.
Using a transcranial magnetic stimulation approach might make it easier to distinguish Alzheimer’s disease from frontotemporal dementia.
Neuroimaging and if necessary, genetic testing, can help to confirm an FTD diagnosis.
Frontotemporal lobar degeneration (FTLD) refers to a group of non-Alzheimer’s dementias that cause portions of the frontal and temporal lobes to atrophy, leading to impairments in behavior, personality, language, and movement. FTLD is estimated to cause up to 10% of dementia cases, and it is the most common cause of dementia in individuals younger than…
